Special Drug Use Investigation for LAMICTAL Bipolar

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Bipolar Disorder

Treatments: Drug: Lamotrigine tablets

Study type: Observational

Funder types: Industry

Identifiers

NCT01428518

115324

Details and patient eligibility

About

This post-marketing surveillance study is designed to collect and assess information on safety and effectiveness of lamotrigine tablets in patients with bipolar disorder in routine clinical practice.

("LAMICTAL" is a trademark of the GlaxoSmithKline group of companies.)

Enrollment: 1,036 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with bipolar disorder
• Patients treated with lamotrigine tablets for the first time

Exclusion criteria

• Not applicable

Trial design

1,036 participants in 1 patient group

Patients with bipolar disorder

Description:

Patients with bipolar disorder prescribed lamotrigine tablets for the first time

Treatment:

Drug: Lamotrigine tablets